Overview
LivaNova Q3 revenue grows 12.5%, beating analyst expectations
Adjusted EPS for Q3 beats consensus, reflecting strong operational performance
Company raises 2025 revenue and EPS guidance, reflecting confidence in growth
Outlook
LivaNova raises full-year 2025 revenue growth guidance to 8.5%-9.5% constant-currency
Company expects 2025 adjusted EPS to be $3.80-$3.90
LivaNova estimates 2025 adjusted free cash flow at $160 mln-$180 mln
Result Drivers
CARDIOPULMONARY GROWTH - Revenue increased 18% driven by Essenz Perfusion System sales and strong consumables demand
NEUROMODULATION GROWTH - Revenue rose 6.9% with growth across all regions
OPERATING MARGIN EXPANSION - Driven by disciplined execution and enhanced productivity
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $357.80 mln | $343.50 mln (7 Analysts) |
Q3 Adjusted EPS | Beat | $1.11 | $0.91 (9 Analysts) |
Q3 EPS | $0.49 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for LivaNova PLC is $60.50, about 10.8% above its November 4 closing price of $53.94
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago
Press Release: ID:nBw8Z7fh2a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)